pharmaceuticals

pharmaceuticals Articles

Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Endo International saw its shares make a solid gain to start off the week after the firm announced preliminary financial results for its third quarter.
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
AbbVie reported better-than-expected third-quarter before the markets opened on Friday due to strong sales of Humira and Imbruvica.
Pharma giant Merck reported mixed third-quarter financial results before the markets opened on Friday.
Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings,...
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These are four top companies for more aggressive investors looking for health care exposure to consider.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for years to come.
With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails.
Spectrum Pharmaceuticals saw its shares make a solid gain early on Wednesday after the firm announced interim data from its mid-stage trial for the treatment of non-small cell lung cancer.
Johnson & Johnson reported better-than-expected fiscal third-quarter financial results before the markets opened on Tuesday.
Infinity Pharmaceuticals saw its shares almost double early on Thursday after the company announced good news.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.